BOSTON, April 3 (Reuters) - Eastbourne Capital Management filed preliminary proxy materials on Friday in its battle to elect five nominees to the board of Amylin Pharmaceuticals Inc (AMLN.O), which makes the diabetes drug Byetta.
BOSTON, April 3 (Reuters) - Eastbourne Capital Management filed preliminary proxy materials on Friday in its battle to elect five nominees to the board of Amylin Pharmaceuticals Inc (AMLN.O), which makes the diabetes drug Byetta.
